Joshua Schafer, Chief Commercial Officer and Executive Vice President of Business Development at Zevra Therapeutics, Inc. (NASDAQ:ZVRA), sold 10,500 shares of the company's common stock on February 13 ...

Clifton R. LaDuane, the Chief Financial Officer and Treasurer of Zevra Therapeutics, Inc. (NASDAQ:ZVRA), recently sold 11,000 shares of the company's common stock. The transaction, which took place on ...

Michael Albert Alrutz, the Senior Vice President and General Counsel at Chimerix Inc . (NASDAQ:CMRX), recently sold a portion of his holdings in the company. Alrutz sold 1,600 shares of common stock ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a pharmaceutical company with a market capitalization of $72.6 million, has ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed that ...